利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.067 秒)

    N3-Pyridyl-Thiamine And Its Use In Cancer Treatments
    24.
    发明申请
    N3-Pyridyl-Thiamine And Its Use In Cancer Treatments 审中-公开
    N3-吡啶基硫胺素及其在癌症治疗中的应用

    公开(公告)号：US20080234304A1

    公开(公告)日：2008-09-25

    申请号：US10594191

    申请日：2005-03-23

    申请人： Jeno Gyuris ,  Ronan C. O'Hagan ,  May Han ,  Murray Robinson ,  Solly Weiler

    发明人： Jeno Gyuris ,  Ronan C. O'Hagan ,  May Han ,  Murray Robinson ,  Solly Weiler

    IPC分类号： A61K31/51 ,  C12N5/00 ,  A61P43/00

    CPC分类号： A61K31/4439

    摘要： The invention provides methods using N3-pyridyl-thiamine compounds and pharmaceutical compositions comprising N3-pyridyl-thiamine, which are especially useful for preventing or reducing tumor growth in vivo. The invention is also directed to the benefits of reducing thiamine concentrations, e.g., by means of a thiamine reduced diet, as an effective step in a therapeutic regime for patients treated with N3-pyridyl-thiamine.

    摘要翻译： 本发明提供了使用N 3 - 吡啶基 - 硫胺素化合物的方法和包含N 3 - 吡啶基 - 硫胺素的药物组合物，其特别可用于预防或减少体内肿瘤生长。 本发明还涉及降低硫胺素浓度的益处，例如通过硫胺素减少饮食，作为用N 3 - 吡啶基硫胺素治疗的患者的治疗方案的有效步骤。

    CDC37 cell-cycle regulatory protein, and uses related thereto
    26.
    发明授权
    CDC37 cell-cycle regulatory protein, and uses related thereto 失效
    CDC37细胞周期调节蛋白，以及与之相关的用途

    公开(公告)号：US5756671A

    公开(公告)日：1998-05-26

    申请号：US625209

    申请日：1996-04-01

    申请人： Jeno Gyuris ,  Lou Lamphere ,  Giulio Draetta

    发明人： Jeno Gyuris ,  Lou Lamphere ,  Giulio Draetta

    IPC分类号： A61K38/00 ,  C07K14/47 ,  C12N9/12 ,  C07K14/00

    CPC分类号： C12N9/1205 ,  C07K14/4738 ,  C12N9/12 ,  A01K2217/05 ,  A61K38/00 ,  C07K2319/00

    摘要： The present invention relates to the discovery in mammalian cells, particularly human cells, of a novel CDK-binding protein, referred to herein as "cdc37". As described herein, this protein functions to facilitate activation and accordingly functions in the modulation of cell-cycle progression, and therefore ultimately of cell growth and differentiation. Moreover, binding data indicated that cdc37 may function coordinately with other cell-cycle regulatory proteins, such as of cyclin-dependent kinases (CDKs), src, p53 and erk kinases.

    摘要翻译： 本发明涉及在哺乳动物细胞，特别是人类细胞中发现新的CDK结合蛋白，本文称为“cdc37”。 如本文所述，该蛋白质起到促进活化作用的作用，因此起到调节细胞周期进程的作用，从而最终导致细胞生长和分化。 此外，结合数据表明cdc37可以与其他细胞周期调节蛋白（例如细胞周期蛋白依赖性激酶（CDK）），src，p53和erk激酶协调起作用。

    Inhibitors of cell-cycle progression, and uses related thereto
    27.
    发明授权
    Inhibitors of cell-cycle progression, and uses related thereto 失效
    细胞周期进展抑制剂及其相关用途

    公开(公告)号：US5672508A

    公开(公告)日：1997-09-30

    申请号：US589981

    申请日：1996-01-23

    申请人： Jeno Gyuris ,  Lou Lamphere ,  David Beach

    发明人： Jeno Gyuris ,  Lou Lamphere ,  David Beach

    IPC分类号： A01K67/027 ,  A61K31/00 ,  A61K35/76 ,  A61K38/00 ,  A61K38/45 ,  A61K48/00 ,  A61P9/00 ,  A61P9/10 ,  A61P17/00 ,  A61P17/14 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07K14/47 ,  C07K19/00 ,  C12N15/09 ,  C12N15/62 ,  C07H21/04

    CPC分类号： C07K14/4738 ,  A01K2217/05 ,  A61K38/00 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/10 ,  C12N2799/022 ,  C12N2799/026 ,  C12N2799/027

    摘要： The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced. More specifically, the inhibitors of the invention are chimeric proteins which include CDK-binding motifs from two or more different proteins. For example, the subject chimeric proteins can be generated from the in-frame fusion of coding sequences from two different CDK inhibitor proteins, such as may be derived from fusion of coding sequences for an INK4 protein and coding sequences for a CIP protein. Chimeric proteins of the present invention have been observed to be more potent inhibitors of cyclin/CDK complexes than were either of the portions of the chimeric protein individually.

    摘要翻译： 本发明涉及细胞周期蛋白依赖性激酶（CDK）的新型抑制剂，特别是CDK /细胞周期蛋白复合物，该抑制剂可用于控制其中引入抑制剂的细胞的增殖和/或分化。 更具体地，本发明的抑制剂是包含来自两种或更多种不同蛋白质的CDK结合基序的嵌合蛋白质。 例如，可以从来自两种不同CDK抑制剂蛋白质的编码序列的框内融合产生受试者嵌合蛋白，例如可衍生自INK4蛋白的编码序列的融合和CIP蛋白的编码序列。 已经观察到本发明的嵌合蛋白比单独的嵌合蛋白的部分中的任一部分更有效的细胞周期蛋白/ CDK复合物抑制剂。